CONMED Corporation

Report azionario NYSE:CNMD

Capitalizzazione di mercato: US$1.5b

CONMED Crescita futura

Criteri Future verificati 3/6

CONMED prevede che gli utili e i ricavi cresceranno rispettivamente di 29.5% e 4.2% all'anno. Si prevede che l'EPS crescerà di 30.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 11.6% in 3 anni.

Informazioni chiave

29.5%

Tasso di crescita degli utili

30.21%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili17.3%
Tasso di crescita dei ricavi4.2%
Rendimento futuro del capitale proprio11.61%
Copertura analitica

Good

Ultimo aggiornamento30 Jul 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Aug 18

CONMED Corporation: Organic Growth Is Masked By Divestitures

Summary Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy. Read the full article on Seeking Alpha
Aggiornamento narrativa • Aug 14

CNMD: Gastro Exit And Potential Sale Interest Will Shape Future Upside

Analysts have raised the implied fair value for CONMED to $45.50 from $39.60, reflecting higher Street price targets clustered around $45 after recent Q2 outperformance, one-time tariff benefits, and renewed interest from potential financial and strategic buyers. Analyst Commentary Recent research on Conmed shows a split between investors focused on potential sale value and those focused on execution risks and relative appeal within medtech.
Aggiornamento narrativa • Jul 31

CNMD: Potential Sale And Surgical Reset Will Shape Next Chapter

Analysts have lifted their fair value estimate for Conmed to $49 from $40. This reflects updated assumptions on growth, profitability, and future P/E that are broadly consistent with recent price target increases to $45 and commentary around potential sale scenarios in the $46 to $53 range.
Aggiornamento narrativa • Jul 16

CNMD: Sale Hopes Will Face Debt And Execution Headwinds Through 2026

CONMED's analyst price target has been modestly reset closer to $36, as analysts weigh slightly higher modeled revenue growth and margins against updated assumptions around valuation multiples and the potential for private equity interest highlighted in recent research. Analyst Commentary Recent research on CONMED reflects a mixed backdrop, with several firms taking a more cautious stance even as takeover speculation and private equity interest attract attention.
Aggiornamento narrativa • Jul 02

CNMD: Gastro Exit And Buybacks Will Support Future Profit Margin Upside

Analysts have lowered their price expectations for CONMED, with the updated target moving to $40. This reflects a shift toward lower assumed revenue growth and P/E multiples, even as projected profit margins edge higher in their models.
Aggiornamento narrativa • Jun 18

CNMD: Refocused Surgical Portfolio And Buybacks Will Test Medtech Reset

Analysts have reset their price target on CONMED to $40, down from $52, citing a broader reassessment of medtech valuations in a year with fewer product cycles, along with rising concerns around healthcare utilization and inflation. Analyst Commentary Recent commentary on CONMED highlights that the lower US$40 price target sits within a broader reset for medtech valuations, rather than being tied to a single company specific issue.
Aggiornamento narrativa • Jun 04

CNMD: Reset Medtech Expectations Will Set Stage For 2026 Guidance Reassessment

Analysts have trimmed their price targets on CONMED, with figures such as BofA cutting its target to $40 and another firm moving to $39. This reflects a reset in medtech valuations, as well as concerns around product execution and limited near term catalysts.
Aggiornamento narrativa • May 20

CNMD: Execution And Margin Stability Will Be Tested In Medtech Reset

Analysts have reduced CONMED's fair value estimate and price target to $40 from $52. They cite a reset in medtech valuations, concerns around product cycles and utilization, and a lower assumed future P/E multiple, while keeping revenue growth and profit margin assumptions broadly steady.
Aggiornamento narrativa • May 01

CNMD: Execution Repairs And Margin Stability Will Support Future Upside

Narrative Update Overview Analysts have trimmed their average price targets on CONMED by $3, alongside neutral ratings and concerns around product execution and a lack of near term catalysts, even as updated assumptions reflect steady revenue growth, profit margins around 10.8% and a slightly lower future P/E multiple. Analyst Commentary Recent research on CONMED has centered on valuation reset, execution around key products, and the search for clear catalysts, with JPMorgan trimming its price target by $3 and other firms shifting to more neutral stances.
Aggiornamento narrativa • Apr 17

CNMD: Execution Questions And Limited Catalysts Will Shape Balanced Risk Profile

Analysts have reset their price target on CONMED to $39, trimming it by $16 from the prior $55. They cite concerns around AirSeal competition, recent execution issues, and a lack of clear near term catalysts for a turnaround in sentiment.
Aggiornamento narrativa • Apr 02

CNMD: Execution Rebound And Margin Focus Will Support Future Upside

The analyst price target for CONMED has been reduced by $3 to $52, as analysts factor in a slightly higher discount rate and a lower future P/E multiple while still modeling modestly higher revenue growth and profit margins, and acknowledging recent downgrades that highlight concerns around execution and a lack of near term catalysts. Analyst Commentary Recent research on CONMED reflects a mixed setup, with some analysts focused on execution risks and a lack of clear near term catalysts, while others maintain a more balanced stance that supports a mid range valuation and steady expectations.
Aggiornamento narrativa • Mar 18

CNMD: Execution Concerns And Leadership Transition Will Shape Balanced Risk Profile

Narrative Update: CONMED Price Target Shift The analyst price target for CONMED has been revised from $42 to $39, with analysts pointing to execution missteps, weaker sentiment around the AirSeal product, and a lack of clear near term catalysts as key reasons for the adjustment. Analyst Commentary Recent Street research on CONMED has tilted more cautious, with several bearish analysts highlighting execution risk, questions around AirSeal, and a limited near term catalyst path to re-rate the shares.
Aggiornamento narrativa • Mar 04

CNMD: Portfolio Refocus And Leadership Change Will Shape Balanced Risk Profile

Narrative Update on CONMED Analysts kept their $42 price target for CONMED unchanged. They cited slightly higher assumed revenue growth and profit margins along with a modestly lower discount rate and future P/E, which together support a steady valuation view despite ongoing sector volatility highlighted in recent research.
Aggiornamento narrativa • Feb 17

CNMD: Portfolio Refocus And Higher Future P/E Will Support Returns

Analysts maintained their fair value estimate for CONMED at $55.00 and refreshed their price target framework to incorporate more conservative assumptions for revenue growth and profit margins, while also reflecting a higher future P/E multiple. Analyst Commentary Bullish analysts appear comfortable holding their US$55.00 fair value estimate for CONMED while updating models to reflect more conservative assumptions for revenue growth and margins.
Aggiornamento narrativa • Feb 03

CNMD: Future Portfolio Shift And Capital Moves Signal Balanced Risk Profile

Analysts have reduced their price target on CONMED to US$42 from US$55, citing a higher discount rate, more conservative revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple in their updated models. Analyst Commentary Bearish analysts are using the lower US$42 price target as a signal that they see less room for upside in CONMED at current levels, especially when they factor in higher discount rates and more cautious revenue assumptions.
Aggiornamento narrativa • Jan 19

CNMD: Gastro Exit And Buybacks Will Support Future Margin Expansion

Analysts modestly adjusted their price target for CONMED, citing a slightly lower discount rate, unchanged fair value of $48.40, and minimal tweaks to long term growth and P/E assumptions that together fine tune their outlook rather than overhaul it. Analyst Commentary Bullish Takeaways Bullish analysts see the steady fair value estimate of $48.40, together with the slightly lower discount rate, as a sign that their view on CONMED’s risk profile and long term earnings power remains intact even after recent fine tuning.
Aggiornamento narrativa • Jan 05

CNMD: Gastro Exit And Buybacks Will Support Margin Expansion Ahead

Analysts have trimmed their price target for CONMED to about US$48.40 from roughly US$54.00, pointing to slightly lower growth assumptions and a reduced future P/E multiple, partly balanced by a marginally higher profit margin outlook. What's in the News CONMED plans to exit its gastroenterology product lines, aiming to focus resources on core areas such as minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair (Key Developments).
Aggiornamento narrativa • Dec 20

CNMD: Focused Surgical Portfolio And Buybacks Will Support Stronger Future Returns

Analysts have lowered their price target on CONMED from 80.00 dollars to 55.00 dollars, citing slightly slower expected revenue growth and a higher discount rate that more than offset improved margin and valuation assumptions. What's in the News CONMED will exit its gastroenterology product lines to focus resources on core areas including minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair.
Aggiornamento narrativa • Dec 06

CNMD: Margin Expansion And Buyback Program Will Drive Strong Future Returns

Analysts have nudged their price target on CONMED slightly higher to $54, citing modestly lower discount rate and revenue growth assumptions, offset by a slightly improved profit margin outlook and a marginally lower future P/E multiple that together support a stable valuation profile. Analyst Commentary Analyst views on CONMED remain balanced, with recent model tweaks reflecting a more nuanced outlook on growth, profitability, and valuation.
Aggiornamento narrativa • Nov 22

CNMD: Margin Initiatives And Robust Buyback Will Drive Long-Term Shareholder Value

CONMED's analyst price target has been reduced from $56 to $54 per share, as analysts cite modest cuts to growth and profit outlooks, along with slightly higher discount rates following recent sector updates. Analyst Commentary Analysts have provided a range of perspectives on CONMED’s outlook based on recent developments in company performance and sector trends.
Aggiornamento narrativa • Nov 07

CNMD: Improving Profit Margins And Robust Buyback Program Will Drive Shareholder Value

CONMED's analyst price target has been lowered from $61 to $56. This change reflects a more cautious stance as analysts point to expectations of slower revenue growth and a higher discount rate, despite improvements in underlying profit margins and future valuation multiples.
Articolo di analisi • Oct 06

These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Reasonably Well

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Articolo di analisi • Sep 12

CONMED (NYSE:CNMD) Has Announced A Dividend Of $0.20

CONMED Corporation ( NYSE:CNMD ) has announced that it will pay a dividend of $0.20 per share on the 3rd of October...
Articolo di analisi • Aug 08

CONMED's (NYSE:CNMD) Solid Profits Have Weak Fundamentals

CONMED Corporation ( NYSE:CNMD ) just reported some strong earnings, and the market reacted accordingly with a healthy...
Articolo di analisi • Jul 03

Are Investors Undervaluing CONMED Corporation (NYSE:CNMD) By 49%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, CONMED fair value estimate is US$107 Current share price of...
Articolo di analisi • May 24

CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20

CONMED Corporation ( NYSE:CNMD ) will pay a dividend of $0.20 on the 3rd of July. This means the dividend yield will be...
Articolo di analisi • May 17

CONMED Corporation's (NYSE:CNMD) Shares Bounce 26% But Its Business Still Trails The Market

Those holding CONMED Corporation ( NYSE:CNMD ) shares would be relieved that the share price has rebounded 26% in the...
Articolo di analisi • Mar 31

Is CONMED (NYSE:CNMD) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Feb 28

Repeated Disappointments On Growth And Margins Leaves Conmed Even Deeper In The Doghouse

Summary Conmed's ambitious revenue growth targets and ongoing operational issues have led to underperformance, with shares down 10% since my last update and ongoing concerns about growth, margins, and tariffs. Despite a decent Q4, Conmed's 2025 guidance was disappointing, with no margin expansion expected and a need to remediate supply and inventory issues. The threatened 25% tariff on goods imported from Mexico could severely affect earnings, adding to the company's existing operational and competitive challenges. While Conmed's valuation appears undemanding, significant risks and uncertainties suggest it may be prudent to wait for clearer signs of improvement before investing. Read the full article on Seeking Alpha
Articolo di analisi • Feb 28

CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20

CONMED Corporation ( NYSE:CNMD ) will pay a dividend of $0.20 on the 4th of April. This means the dividend yield will...
Articolo di analisi • Feb 08

CONMED Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Shareholders might have noticed that CONMED Corporation ( NYSE:CNMD ) filed its full-year result this time last week...

Previsioni di crescita degli utili e dei ricavi

NYSE:CNMD - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20281,5111431671735
12/31/20271,4341351651837
12/31/20261,3661172141537
6/30/20261,37256134151N/A
3/31/20261,37155124143N/A
12/31/20251,37547151171N/A
9/30/20251,34764149168N/A
6/30/20251,326110148165N/A
3/31/20251,316119165179N/A
12/31/20241,307132154167N/A
9/30/20241,288132166180N/A
6/30/20241,27699159175N/A
3/31/20241,26282142158N/A
12/31/20231,24564106125N/A
9/30/20231,169583857N/A
6/30/20231,139881637N/A
3/31/20231,099-94729N/A
12/31/20221,045-811233N/A
9/30/20221,069-835979N/A
6/30/20221,042-1145674N/A
3/31/20221,020687490N/A
12/31/20211,0116397112N/A
9/30/2021989628398N/A
6/30/20219795499112N/A
3/31/2021881137083N/A
12/31/2020862105265N/A
9/30/202087406985N/A
6/30/202087006987N/A
3/31/202095134N/A103N/A
12/31/201995529N/A95N/A
9/30/201993329N/A79N/A
6/30/201990128N/A47N/A
3/31/201987631N/A46N/A
12/31/201886041N/A75N/A
9/30/201884072N/A71N/A
6/30/201882873N/A80N/A
3/31/201881271N/A75N/A
12/31/201779655N/A66N/A
9/30/201777815N/A58N/A
6/30/201777316N/A70N/A
3/31/201776912N/A72N/A
12/31/201676415N/A40N/A
9/30/201675016N/A36N/A
6/30/201673517N/A24N/A
3/31/201672222N/A17N/A
12/31/201571930N/A51N/A
9/30/201572334N/A64N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di CNMD ( 29.5% all'anno) è superiore al tasso di risparmio ( 3.7% ).

Guadagni vs Mercato: Si prevede che gli utili di CNMD ( 29.5% all'anno) cresceranno più rapidamente del mercato US ( 16.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di CNMD cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CNMD ( 4.2% all'anno) crescerà più lentamente rispetto al mercato US ( 12.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CNMD ( 4.2% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di CNMD sarà basso tra 3 anni ( 11.6 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/08/20 19:56
Prezzo dell'azione a fine giornata2026/08/20 00:00
Utili2026/06/30
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

CONMED Corporation è coperta da 16 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Travis SteedBarclays
Vikramjeet ChopraBMO Capital Markets Equity Research
Travis SteedBofA Global Research